Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 8/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925653 | 0.85 | CYP1A2 (0.43) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2928787 | 0.83 | CNR2 (0.41) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2921345 | 0.81 | PTGS2 (0.43) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2926100 | 0.78 | CNR2 (0.42) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2926006 | 0.78 | PTGS2 (0.41) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2925246 | 0.77 | PTGS2 (0.41) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2922392 | 0.77 | CNR2 (0.46) | PTGS2CNR2CNR1 | |
| SCHEMBL2924583 | 0.77 | PTGS2 (0.41) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2922100 | 0.77 | CNR2 (0.42) | PTGS2CNR2USP2CYP1A2CYP3A4 | |
| SCHEMBL2927533 | 0.76 | THRB (0.44) | PTGS2CNR2USP2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086950-B1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-23 | — | — | US | disclosed |
| US-6875770-B2 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6673797-B1 | CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1086950-A1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137202-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | PTGS2, IDO2, IDO1 | PTGS2 1/4885CNR2 21/4885USP2 1488/4885 |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | IDO1, PTGS1, IDO2 | PTGS2 4/4885CNR2 25/4885USP2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.